BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002240
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธAlbany Med College, Albany, New York, United States
๐บ๐ธClinsites / Sorra Research Ctr, Birmingham, Alabama, United States
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
- Conditions
- AIDS Dementia ComplexHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT00002246
- Locations
- ๐บ๐ธ
AIDS ReSEARCH Alliance, West Hollywood, California, United States
๐บ๐ธMount Sinai Hosp, New York, New York, United States
๐ฌ๐งCharing Cross and Westminster Med School, London SW 10, United Kingdom
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 730
- Registration Number
- NCT00005918
- Locations
- ๐บ๐ธ
The CORE Ctr, Chicago, Illinois, United States
๐บ๐ธUniv of Texas Med Branch, Galveston, Texas, United States
Tan tock Seng Hosp
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00002224
- Locations
- ๐บ๐ธ
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
๐บ๐ธUniv of Kansas School of Medicine, Wichita, Kansas, United States
๐บ๐ธBeacon Clinic / Boulder Community Hosp, Boulder, Colorado, United States
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002411
- Locations
- ๐บ๐ธ
Northwestern Univ / Div of Infect Diseases, Chicago, Illinois, United States
๐บ๐ธRush Presbyterian / ST Lukes Med Ctr, Chicago, Illinois, United States
๐บ๐ธUniv of Texas / Med Branch at Galveston, Galveston, Texas, United States
A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002207
- Locations
- ๐บ๐ธ
ID Care Inc, Somerville, New Jersey, United States
๐บ๐ธFanno Creek Clinic, Portland, Oregon, United States
๐บ๐ธDr Iraj Mirshahi, Richmond, Virginia, United States
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002176
- Locations
- ๐บ๐ธ
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Study Comparing Two Forms of Didanosine in HIV-infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00002360
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002177
- Locations
- ๐บ๐ธ
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00002429
- Locations
- ๐บ๐ธ
NJCRI, Newark, New Jersey, United States
๐บ๐ธUniv of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
๐จ๐ฆClinique Medicale L'Actuele, Montreal, Quebec, Canada